Atherotech Diagnostics Lab Announces 2012 Sponsorship Grant to National Lipid Association
Atherotech Diagnostics Lab Announces 2012
Sponsorship Grant to National Lipid Association
BIRMINGHAM, Ala. — March 6, 2012 —Atherotech Diagnostics Lab announces
its 2012 Sponsorship Agreement with the National Lipid Association (NLA). The agreement
provides support in the form of a grant to further the NLA’s mission of lipid education and management in clinical medicine
and includes support of educational programs at regional conferences.
“It’s rewarding to see the value that Atherotech places on our mission of education and advancing the practice of
clinical lipidology for the NLA and its members,” said Christopher Seymour, Executive Director of the National Lipid
Association. “The NLA greatly appreciates this generous grant in support of our educational programming and
Atherotech upholds the educational mission of the NLA and contributes to its goals of engaging members in clinical
lipidology. Atherotech will partner with the NLA to offer advanced lipid testing and inflammatory markers seminars and
support the organization’s three scientific meetings:
Spring Clinical Lipid Update held March 9-11 in San Diego, Calif.
NLA Annual Scientific Sessions held May 31-June 3 in Scottsdale, Ariz.
Summer Clinical Update September 14-16 in Charlotte, N.C.
“Atherotech is committed to educating the physician community on advances in improved cardiovascular risk assessment and
personalized treatment strategies to improve patient outcomes,” said Atherotech CEO Michael Mullen. “We’re proud to support
the NLA in its mission.”
The NLA is a nonprofit, multidisciplinary medical society of more than 3,000 members dedicated to enhancing lipid
management in clinical practice and reducing mortalities associated with atherosclerotic disease. The association provides
a comprehensive educational approach for the community of practitioners in the field of clinical lipidology, which embraces
lipid and lipoprotein metabolism, cardiometabolic disorders and obesity.
Atherotech’s VAP Test
Cardiovascular disease is the leading cause of death in the U.S., killing more than 1 million people each year.
Atherotech’s VAP Cholesterol Test for patients at risk for cardiovascular disease helps clinicians improve the detection,
evaluation and management of heart disease risk.
The VAP Test is the only expanded lipid test that routinely reports directly measured LDL, which is included in the 22
reported cholesterol components — all at no additional cost. These components include Lp(a), apoB, apoA1, and the
apoB/apoA1 ratio, making the VAP Test the only lipid profile that routinely reports all three lipid parameters — LDL, non-
HDL and apoB — considered necessary by the American Diabetes Association and American College of Cardiology. The
comprehensive lipid profile also identifies markers of metabolic syndrome, often associated with early diabetes.
About Atherotech Diagnostics Lab Atherotech is a CLIA-certified clinical reference laboratory and
cardiodiagnostic company focusing on cardiometabolic tests, including the company’s patented VAP Cholesterol Test, which
reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to
comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is
accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is
reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.atherotech.com.